Metabolic drug interactions with newer antipsychotics: a comparative review. - Wikidata - wikimedia - TriplyDB

Metabolic drug interactions with newer antipsychotics: a comparative review.

Metabolic drug interactions with newer antipsychotics: a comparative review.

http://www.wikidata.org/entity/Q36703845

about

Evaluation of the clinical efficacy of asenapine in schizophrenia Optimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatment New atypical antipsychotics for schizophrenia: iloperidone Plasma quetiapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2000-2011 Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.Classics in Chemical Neuroscience: Aripiprazole.Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS/MS.Schizophrenia: overview and treatment options.A mechanistic insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity.Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease Can valproic acid be an inducer of clozapine metabolism?Psychiatric treatment considerations with direct acting antivirals in hepatitis C Clinically significant psychotropic drug-drug interactions in the primary care setting.The promise and reality of pharmacogenetics in psychiatry Role of aripiprazole in treatment-resistant schizophrenia.Long term effects of smoking cessation in hospitalized schizophrenia patients.Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia.Prescribing clozapine and rifampicin: clinical impact of their interaction.The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.Routine pharmacogenetic testing in clinical practice: dream or reality?Pharmacogenetics in psychiatry: are we ready for widespread clinical use?Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder.Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.A review of the safety and tolerability of aripiprazole.Pharmacogenetic considerations in the treatment of psychiatric disorders.Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice.Antipsychotic drug toxicology in children.Factors affecting interindividual differences in clozapine response: a review and case report.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Interactions between antiepileptics and second-generation antipsychotics.Clinically significant drug interactions with atypical antipsychotics.Adverse effects of clozapine in older patients: epidemiology, prevention and management.Clinically relevant interactions between newer antidepressants and second-generation antipsychotics.Polypharmacy in the treatment of subjects with intellectual disability.Clinical applications of CYP genotyping in psychiatry.

P2860

Q24630385-213F98DE-D095-4A86-82C3-EA3D8E47FC33 Q26799098-C28950ED-CC52-4154-A11A-3587C169973C Q30482195-09F27560-42F3-4F6A-9C97-F85195493907 Q30685511-326696DD-8B4C-4AD2-87D0-7923D96D8634 Q33799660-177811E1-7433-40B8-9F3B-F6BD4191E31B Q33866125-F07B40AB-3E54-4A80-8B17-5250C7264545 Q34126160-93EE1D35-28B9-43A3-87E1-75B4D53650B0 Q34154951-B756B25C-FA64-4009-B9A7-CC1FDC8B22AA Q34239110-AC3B6FC1-8743-496D-B3BF-FF0968ED0D90 Q34329829-1C0D1323-F579-4DAD-8F06-E1B088405236 Q34466749-0107C9B2-CAAF-4C24-8D38-4B121712E604 Q34497477-E9BB9AC6-B0DC-448B-91AA-DD05F5696D6E Q34721628-ADDB9C6C-EC91-43ED-9708-B257CB2E823C Q35104220-D86C6FD8-8A34-4E98-82D2-E5C9387AA082 Q35226451-638A1B5D-CA9A-4554-AF8C-946760258A95 Q36026776-65D2D9FB-89E8-4A0F-A8D7-CC2C9DFA1235 Q36300051-E9920523-ACFB-4168-B944-9DF567AE12BF Q36537180-0F15A2A9-3515-4902-A31A-8480ACF851AA Q36873906-9C5136A1-9FBA-4367-B85C-E3DB4AA4BBDC Q36953235-A5866DEF-8BF2-4CB8-B7C9-689FEC3781CD Q36984231-9DE70EF7-19D0-4014-9932-29945A455BE4 Q36989859-EAAE95A3-1A34-4E9A-83EE-36E743C4D9FF Q37076472-8AC4A82E-FAB5-439E-B2FF-6640EDB0322C Q37161513-5D38792E-F8A0-484F-B726-120161093DC5 Q37287980-5B0DEEAE-8F19-40BE-8B58-DD76A8ACD5E9 Q37358661-51E0C70C-4098-4FB6-8795-831B8BC3DD41 Q37397705-C44684B6-5296-4279-9A23-523E1F63B339 Q37422493-071BC91F-CCE4-4DD8-B069-8FEC1014AA8D Q37510958-0126EBB5-330B-40F1-99AA-70C3F5F13035 Q37681573-A3ACBECF-947F-40D0-B52B-82FDAC6FC48D Q37714573-2D781D58-5A91-42C3-8B80-ECC1FA05CFFE Q37852719-6592F008-DF83-4EDF-B0D3-ACF26ADEBB25 Q37860249-A76A46CC-3EC3-4A0E-88B4-F7D4FF15802B Q37952823-B2224A31-7027-4C1C-9388-680127FAF75A Q37983921-90436631-7C55-4A97-8D53-0AAC6F7350B9 Q38156416-4B14DB99-A269-4AFD-A5BF-485350DDB431 Q38171350-8A997D3C-1F68-4474-9FA5-5DCF332A8D62 Q38185057-A750E5FD-1A0A-4CD3-9087-CAF5459BB3A2 Q38214474-DDB07AAE-9C67-4E70-8C58-4317A7616E9C Q38247063-60BB44B2-6240-4B0B-AF08-35AF63675B13

P2860

Metabolic drug interactions with newer antipsychotics: a comparative review.

http://www.wikidata.org/entity/Q36703845

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Metabolic drug interactions with newer antipsychotics: a comparative review.

@ast

Metabolic drug interactions with newer antipsychotics: a comparative review.

@en

type

label

Metabolic drug interactions with newer antipsychotics: a comparative review.

@ast

Metabolic drug interactions with newer antipsychotics: a comparative review.

@en

prefLabel

Metabolic drug interactions with newer antipsychotics: a comparative review.

@ast

Metabolic drug interactions with newer antipsychotics: a comparative review.

@en

P1433

Q36703845-21B4E849-1B48-4C4D-BE45-ABA215A1B782

P1476

Q36703845-660BB930-527F-4D8F-81EF-C6A0EB6171FD

P2093

Q36703845-10AA095C-4960-4B55-B99B-4A406744B696

Q36703845-FFE235B2-0904-41AB-8E9F-58F510E5324F

P2860

Q36703845-03E83E71-EBE9-43E8-877C-E94E23A5C629

Q36703845-044F2C1A-2B95-4201-B2CA-8C3C8CC46E2F

Q36703845-08AAC7B8-3BF4-472D-AFA7-8C2C584BE6AE

Q36703845-0DC82A7E-22D0-4EDC-8B4F-7C72C0E55333

Q36703845-108C1930-36D6-4137-986E-7E3754267905

Q36703845-10C1FC94-A7F7-4B8B-8E0B-5D9DB77B95DF

Q36703845-11244F2B-98D9-4D9C-8430-938B6A6838EB

Q36703845-11BB0FD6-2CCE-4B1C-B818-21A36CECCD46

Q36703845-168B0701-B482-491C-B4CA-6C1263E7B007

Q36703845-19CAE76D-543D-44EF-A9B7-00EC8B3065BD

P304

Q36703845-10CF6C55-911D-40D1-93AA-EAC1C927E132

P31

Q36703845-37ACBB73-E408-4CA1-AB6D-07AB7E70930F

P356

Q36703845-E081AAE5-DF36-4A8E-973A-2E5C1870B8FB

P433

Q36703845-8A51CD3C-382C-4FE9-902B-71EDD672B405

P478

Q36703845-7FD2BB97-A632-46F5-AD19-7B7A0D35286C

P50

Q36703845-6B0E31E7-5634-47D5-A05E-31238E85D5E7

Q36703845-AD964B27-31CF-4749-A1DC-E59CB9325AC2

P577

Q36703845-F479B099-96BA-4904-A9FD-141988862B4F

P5875

Q36703845-13E0E74C-9A97-494F-B313-A011F92EF41E

P698

Q36703845-8B7EA53F-BE22-413D-95B4-11BE29DD0E0A

P356

J.1742-7843.2007.00017.X

P1433

Basic and Clinical Pharmacology and Toxicology

P1476

Metabolic drug interactions with newer antipsychotics: a comparative review

@en

P2093

Edoardo Spina

http://www.w3.org/2001/XMLSchema#string

Jose de Leon

http://www.w3.org/2001/XMLSchema#string

P2860

The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers

The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers

Drug glucuronidation in clinical psychopharmacology

A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers

The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes

Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.

Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration.

The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.

P304

4-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1742-7843.2007.00017.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6586097

http://www.w3.org/2001/XMLSchema#string

P698

17214606

http://www.w3.org/2001/XMLSchema#string